• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤大小和p16状态对治疗结果的影响——前瞻性随访的口咽肿瘤患者完全缓解的实现情况。

Effect of Tumor Size and p16 Status on Treatment Outcomes - Achievement of Complete Remission in Prospectively Followed Patients with Oropharyngeal Tumors.

作者信息

Slavik M, Kazda T, Selingerová I, Šána J, Ahmad P, Gurín D, Hermanová M, Novotný T, Červená R, Dymáčková R, Burkoň P, Slabý O, Šlampa P

出版信息

Klin Onkol. 2019 Winter;32(1):58-65.

PMID:30764631
Abstract

BACKGROUND

Oropharyngeal squamous cell tumors associated with human papillomavirus infection (p16 positive tumors) have better prognosis than p16 negative tumors regardless of the more advanced stage of the disease. Tumor volume (GTVt+n) is generally an important factor affecting treatment results of ionizing radiation. The aim of this prospective non-randomized study is to evaluate the effect of tumor volume on the (chemo)radiation treatment results in a group of patients with p16 negative and p16 positive oropharyngeal tumors.

PATIENTS AND METHODS

Patients with confirmed squamous cell tumor of the oropharynx of stages III and IV, according to the 7th version of the TNM (tumor-nodes-metastases) classification, were eligible for this study. The main exclusion criteria were palliative treatment, neoadjuvant chemotherapy or planned concomitant therapy with cetuximab. Patients were treated according to standardized protocols with curative intent. Primary tumor volume (GTVt) and involved nodes volume (GTVn) were obtained from radiotherapy planning system for further statistical analysis. The differences in tumor volumes between the groups according to p16 expression were assessed with subsequent testing of probability to achieve complete remission (CR) of the disease in both groups.

RESULTS

In total, 49 patients - 84% men, median age 60.5 years, 25 (51%) patients p16 positive, 40 (82%) underwent concomitant chemoradiotherapy. Median of GTVt in the whole patients group is 40.2 ccm, GTVn 11.78 ccm and median volume of the whole tumor burden (GTVt+n) 70.21 ccm (range 11.05-249). Median of GTVn was greater in the p16 positive cohort (p = 0.041). In the entire group, the median time to reach CR was 91 days (95% CI 86-107 days) from the end of radiotherapy. In the group of p16 negative patients, 14 achieved CR (61%) out of 23 patients, in p16 positive group 20 (80%) out of 25 patients (p = 0.111). P16 negative patients had a longer time to CR (p = 0.196, HR 1.58, 95% CI 0.79-3.18). None of the independently assessed volumetric parameters of the tumor (GTVt, GTVn, GTVt+n) affected CR in the p16 positive patients group, while there was a significant impact of the whole tumor burden (GTVt+n) in the p16 negative cohort (median 58.1 ccm in CR patients vs. 101.9 ccm, p = 0.018).

CONCLUSION

We have showed less GTVt+n dependence to achieve CR in p16 positive tumors in comparison with p16 negative tumors. Thus, p16 positive oropharyngeal squamous cell cancers should not be withdrawn from the curative treatment intent based on the greater GTVt+n. Key words oropharyngeal neoplasms - p16 status - treatment outcome - tumor burden - complete remission This work was supported by grant of the Ministry of Health of the Czech Republic AZV 15-31627A and by grant of the Ministry of Health of the Czech Republic - Conceptual development of a research organization (MMCI 00209805). The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 2. 11. 2018 Accepted: 11. 11. 2018.

摘要

背景

与人乳头瘤病毒感染相关的口咽鳞状细胞肿瘤(p16阳性肿瘤),无论疾病分期如何进展,其预后均优于p16阴性肿瘤。肿瘤体积(GTVt+n)通常是影响电离辐射治疗效果的重要因素。这项前瞻性非随机研究的目的是评估肿瘤体积对一组p16阴性和p16阳性口咽肿瘤患者(放)化疗治疗效果的影响。

患者与方法

根据TNM(肿瘤-淋巴结-转移)分类第7版确诊为III期和IV期口咽鳞状细胞肿瘤的患者符合本研究条件。主要排除标准为姑息治疗、新辅助化疗或计划联合西妥昔单抗治疗。患者按照具有治愈意图的标准化方案进行治疗。从放射治疗计划系统中获取原发肿瘤体积(GTVt)和受累淋巴结体积(GTVn),用于进一步的统计分析。根据p16表达评估两组之间肿瘤体积的差异,并随后测试两组疾病实现完全缓解(CR)的概率。

结果

总共49例患者,男性占84%,中位年龄60.5岁,25例(51%)患者p16阳性,40例(82%)接受同步放化疗。整个患者组GTVt的中位数为40.2立方厘米,GTVn为11.78立方厘米,整个肿瘤负荷(GTVt+n)的中位数为70.21立方厘米(范围11.05 - 249)。p16阳性队列中GTVn的中位数更大(p = 0.041)。在整个组中,从放疗结束到达到CR的中位时间为91天(95%CI 86 - 107天)。在p16阴性患者组中,23例患者中有14例(61%)实现CR,在p16阳性组中,25例患者中有20例(80%)实现CR(p = 0.111)。p16阴性患者达到CR的时间更长(p = 0.196,HR 1.58,95%CI 0.79 - 3.18)。在p16阳性患者组中,肿瘤的任何独立评估的体积参数(GTVt、GTVn、GTVt+n)均未影响CR,而在p16阴性队列中,整个肿瘤负荷(GTVt+n)有显著影响(CR患者中位数为58.1立方厘米,对比101.9立方厘米,p = 0.018)。

结论

我们已经表明,与p16阴性肿瘤相比,p16阳性肿瘤实现CR对GTVt+n的依赖性较小。因此,不应基于更大的GTVt+n而放弃对p16阳性口咽鳞状细胞癌的治愈性治疗意图。关键词口咽肿瘤 - p16状态 - 治疗结果 - 肿瘤负荷 - 完全缓解 本研究得到捷克共和国卫生部AZV 15 - 31627A资助以及捷克共和国卫生部 - 研究机构概念发展(MMCI 00209805)资助。作者声明他们在研究中使用的药物、产品或服务方面没有潜在利益冲突。编辑委员会声明该手稿符合ICMJE对生物医学论文的推荐标准。提交日期:2018年11月2日 接受日期:2018年11月11日

相似文献

1
Effect of Tumor Size and p16 Status on Treatment Outcomes - Achievement of Complete Remission in Prospectively Followed Patients with Oropharyngeal Tumors.肿瘤大小和p16状态对治疗结果的影响——前瞻性随访的口咽肿瘤患者完全缓解的实现情况。
Klin Onkol. 2019 Winter;32(1):58-65.
2
Prognosis of HPV-Positive and -Negative Oropharyngeal Cancers Depends on the Treatment Modality.人乳头瘤病毒阳性和阴性口咽癌的预后取决于治疗方式。
Klin Onkol. 2019 Spring;32(3):187-196.
3
Current Perspective on HPV-Associated Oropharyngeal Carcinomas and the Role of p16 as a Surrogate Marker of High-Risk HPV.人乳头瘤病毒相关口咽癌的当前观点及p16作为高危人乳头瘤病毒替代标志物的作用
Klin Onkol. 2019 Summer;32(4):252-260. doi: 10.14735/amko2019252.
4
Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.颈部淋巴结外囊扩展和人乳头瘤病毒 16-DNA 缺失是 p16 阳性口咽鳞癌生存受损的预测因素。
Cancer. 2020 Jan 1;126(9):1856-1872. doi: 10.1002/cncr.32667. Epub 2020 Feb 7.
5
The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.辅助化疗在手术治疗的p16阳性口咽鳞状细胞癌中的作用
JAMA Otolaryngol Head Neck Surg. 2017 Mar 1;143(3):253-259. doi: 10.1001/jamaoto.2016.3353.
6
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.在IMCL-9815 III期注册试验中,人乳头瘤病毒和p16状态与局部晚期头颈部口咽鳞状细胞癌患者接受放疗联合或不联合西妥昔单抗治疗的预后的相关性。
J Clin Oncol. 2016 Apr 20;34(12):1300-8. doi: 10.1200/JCO.2015.62.5970. Epub 2015 Dec 28.
7
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.基于铂类药物的新辅助治疗对携带BRCA1和BRCA2种系突变患者的疗效——对布尔诺MMCI治疗的乳腺癌患者的回顾性分析
Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31.
8
Stereotactic Body Radiotherapy - Current Indications.立体定向体部放射治疗——当前适应症
Klin Onkol. 2019 Winter;32(1):10-24. doi: 10.14735/amko201910.
9
p16 status and interval neck dissection findings after a 'clinically complete response' to chemoradiotherapy in oropharyngeal squamous cell carcinoma.口咽鳞状细胞癌对放化疗“临床完全缓解”后的p16状态及颈部淋巴结清扫结果
J Laryngol Otol. 2015 Aug;129(8):801-6. doi: 10.1017/S0022215115001139. Epub 2015 Jun 19.
10
Stereotactic Body Radiotherapy of Lymph Node Oligometastases.立体定向体部放疗治疗淋巴结寡转移。
Klin Onkol. 2020 Spring;33(2):114-122. doi: 10.14735/amko2020114.

引用本文的文献

1
NECKCHECK PROJECT: enhancing diagnostic accuracy in oropharyngeal squamous cell carcinoma through computer-based radiological tools.颈部检查项目:通过基于计算机的放射学工具提高口咽鳞状细胞癌的诊断准确性。
Sci Rep. 2025 Jun 4;15(1):19645. doi: 10.1038/s41598-025-03895-8.
2
Tumour volume and radiotherapy prolongation in locally advanced head and neck cancer patients treated with radical IMRT.接受根治性调强放疗的局部晚期头颈癌患者的肿瘤体积与放疗延长情况
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Dec;166(4):405-411. doi: 10.5507/bp.2021.047. Epub 2021 Aug 24.